In late May 2021, the latest study data concerning Beovu safety issues resulted in Novartis stopping three key clinical trials — MERLIN, RAPTOR, and RAVEN — as well as Novartis indicating there will be another Beovu label change. To see how Novartis is seeking to present the current status of its lingering Beovu safety issues as well as the next … [Read more...]
New Elmiron Medication Guide Points Out Retinal Pigmentary Eye Problems
The new Elmiron Medication Guide mandated by the FDA Center for Drug Evaluation and Research (CDER) in March 2021 follows and reiterates the June 2020 Elmiron label change that added warning about the pigmentary maculopathy Elmiron side effect. We point out that before the June 2020 Elmiron label change adding this new warning about the … [Read more...]
Beovu Lawsuits Lawyer / Law Firm Handles Individuals’ Cases, Not Beovu Class Actions
We want to clear up some possible confusion. If a patient has vision loss or blindness after getting Beovu injections in their eyes, this person must contact a lawyer or law firm to handle their Beovu case in order to get legal compensation for the Beovu drug injury they have suffered. That is because Beovu lawsuits are being filed as individual … [Read more...]
Elmiron Can Double the Risk of Pigmentary Maculopathy or Macular Degeneration
Elmiron (pentosan polysulfate sodium, or PPS) was approved by the FDA way back in September 1996 for the treatment of painful bladder syndrome (interstitial cystitis). Over the past several years, however, cases of Elmiron-related eye damage have been reported. Remarkably, according to a recent medical study, patients with high levels of Elmiron … [Read more...]
Beovu Side Effects and Beovu Lawsuits for Patients Complicate Future for Beovu
Given the serious nature and number of Beovu side effects reported to date, together with the Beovu lawsuits filed against Novartis for patients with severe vision loss, it seems fair to say that things look a bit grim for Beovu and Novartis at the start of 2021. So what does the path forward look like for Beovu? Let’s start with where things … [Read more...]
Maculopathy Patients Should be Asked About Any Elmiron Use in Past
A new Elmiron medical study about cases of macular toxicity related pentosan polysulfate (PPS) exposure suggests that established maculopathy patients should be questioned regarding any Elmiron use in the past. This will help eye doctors determine whether this person may have Elmiron maculopathy secondary to PPS toxicity. The findings of this … [Read more...]
Elmiron Legal Cases for Eye Damage and Retinal Injury Are Consolidated in Elmiron MDL
In December 2020, all Elmiron legal cases alleging eye damage and retinal injury filed in the federal courts were consolidated by means of an Elmiron MDL Order. These Elmiron legal cases are noteworthy as regards the monetary damages aspect of a lawsuit because these Elmiron-related eye problems can lead to vision loss or blindness. From the … [Read more...]
Beovu: What Comes Next for This Troubled Novartis AMD Eye Injection?
As we start 2021, let’s look at where things currently stand with the Beovu “safety issue” — Beovu adverse drug reactions and Beovu-related eye problems — and how we got here. In the 15 months since Beovu was approved by the FDA in October 2019, there have been numerous reports of Beovu causing occlusive retinal vasculitis, retinal artery … [Read more...]
Elmiron Updates: Legal, Medical, and Regulatory – December 2020
In our final Drug Injury Watch article for 2020 we want to report on the recent developments regarding Elmiron lawsuits, Elmiron side effects warnings, and Elmiron pigmentary maculopathy diagnosis methods. As regards the increasing number of Elmiron lawsuits for patients who have suffered vision loss due to Elmiron pigmentary maculopathy, there … [Read more...]
Beovu Retinal Vasculitis Made Worse by a Later Lucentis Treatment
A recent medical journal article presents an interesting case report about a 76-year-old woman with Beovu-related retinal vasculitis which was made worse by a later Lucentis treatment for her wet AMD. That patient's doctors are the authors of "Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A … [Read more...]